FRM
HRTX icon

Fox Run Management’s Heron Therapeutics HRTX Stock Holding History

Fox Run Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,868
Closed -$249K – 599
2018
Q3 		$249K Buy
+7,868
New +$293K 0.11% 414
2018
Q1 		– Sell
-22,050
Closed -$399K – 801
2017
Q4 		$399K Buy
22,050
+4,750
+27% +$77.5K 0.12% 359
2017
Q3 		$279K Sell
17,300
-12,800
-43% -$201K 0.08% 522
2017
Q2 		$417K Buy
+30,100
New +$436K 0.14% 291

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Fox Run Management's HRTX Position: Q4 2018 in Review

Fox Run Management sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 7,868 shares — an estimated $249K sold.

Fox Run Management first reported a position in HRTX in Q2 2017 and held it in 4 quarters. The position peaked at $417K in Q2 2017. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

  • Fox Run Management reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Fox Run Management sold 7,868 Heron Therapeutics shares in Q4 2018, an estimated $249K.
  • Fox Run Management first reported a position in Heron Therapeutics in Q2 2017 and held it in 4 quarters.
  • Fox Run Management's Heron Therapeutics position peaked at $417K in Q2 2017.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Fox Run Management's 13F filing for Q4 2018, filed 15 Jan 2019.